Sumitomo Mitsui Trust Group Inc. Grows Position in DaVita Inc. $DVA

Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of DaVita Inc. (NYSE:DVA) by 4.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 113,503 shares of the company’s stock after buying an additional 4,404 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.15% of DaVita worth $16,169,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Concurrent Investment Advisors LLC acquired a new position in shares of DaVita during the 1st quarter valued at about $223,000. Wealth Enhancement Advisory Services LLC lifted its position in DaVita by 22.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company’s stock valued at $666,000 after buying an additional 800 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in DaVita by 7.9% in the first quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company’s stock valued at $8,452,000 after buying an additional 4,048 shares during the last quarter. OneDigital Investment Advisors LLC acquired a new position in DaVita in the first quarter valued at about $200,000. Finally, Teacher Retirement System of Texas acquired a new position in DaVita in the first quarter valued at about $1,010,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the topic of several research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. Truist Financial set a $140.00 price target on shares of DaVita in a research note on Tuesday, October 14th. Barclays decreased their price objective on DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a report on Thursday, October 9th. Bank of America decreased their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Finally, Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $153.25.

DaVita Stock Performance

DaVita stock opened at $126.25 on Thursday. DaVita Inc. has a one year low of $122.93 and a one year high of $179.60. The business has a fifty day moving average of $131.59 and a two-hundred day moving average of $137.01. The company has a market cap of $9.03 billion, a P/E ratio of 12.41, a price-to-earnings-growth ratio of 0.93 and a beta of 1.13.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.29 by ($0.78). DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the company posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.